Chemical and life sciences risk issue video series

Mitigating risks in IPO and De-SPAC

In this video, alongside Marsh experts, we cover some of the key risks in an IPO and a De-SPAC transaction within the chemical and life sciences industry, and how D&O insurance may help mitigate some of the risks.

Health care researchers working in life science laboratory

In this video Jenny Yu, Chemical and Life Sciences Industry Leader for Marsh is joined by Charles Ringrose, Public Offering Lead for Marsh Specialty.


Together they cover some of the key risks in an IPO and a De-SPAC transaction within the Life Sciences Industry, and how D&O insurance may help mitigate some of the risks. There are a number of financial benefits of an IPO, SPAC merger / De-SPAC, however, this does mean materially changing a company’s risk profile, by adding significant exposure to the personal assets of a company’s Directors and Officers.

This video offers practical advice on these types of risks, and how they can be mitigated from a D&O insurance perspective. Finally considering the 2022 outlook for the Life Sciences sector.
 

Meet our speakers

Image placeholder

Jenny Yu

Chemicals and Life Sciences Industry Leader, UK & Ireland

Image placeholder

Charles Ringrose

Public Offerings Lead, FINPRO, Private Equity and M&A, Marsh Specialty

Related articles